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Purpose: Luseogliﬂozin, a sodium-glucose cotrans-
porter-2 inhibitor, may be beneﬁcial in obese diabetic
patients based on its potential to decrease blood
glucose and body weight, but there is limited proof.
This analysis aimed to investigate the efﬁcacy and
safety of luseogliﬂozin in patients with varying levels
of obesity.
Methods: A pooled analysis of four 52-week Phase
III trials of luseogliﬂozin 2.5 mg daily (or up to 5 mg
daily) in Japanese patients with type 2 diabetes mellitus
stratiﬁed according to baseline body mass index (BMI)
was conducted. Efﬁcacy end points included changes
in glycosylated hemoglobin (HbA1c), fasting plasma
glucose (FPG), and body weight.
Findings: In total, 1031 patients were included and
stratiﬁed into 5 BMI (kg/m2) groups: low-to-medium
(o22.5, n ¼ 222); medium (Z22.5 too25, n ¼ 270);
high-level 1 (Z25 to o27.5, n ¼ 262); high-level
2 (Z27.5 to o30, n ¼ 142); and very-high (Z30,
n ¼ 135). HbA1c decreased signiﬁcantly compared
with baseline until week 52 in all groups, and a similar
trend was observed with FPG and body weight. The
reduction in glycemic parameters tended to be slightly
smaller in patients with BMI o22.5 kg/m2, and the
reduction in body weight tended to be greater in
patients with higher BMI, especially those with BMIApril 2016Z30 kg/m2. Levels of fasting insulin, C-peptide
immunoreactivity, triglyceride, blood pressure, aspar-
tate aminotransferase, alanine aminotransferase, and
uric acid decreased signiﬁcantly at week 52 in all
groups (except for aspartate aminotransferase in
patients with BMI o22.5 kg/m2). Levels of these
parameters tended to be higher at baseline and these
enhanced levels resulted in a greater decrease in
patients with higher BMI. In safety, the incidence of
adverse events was similar between groups, and most
of them were mild in severity.
Implications: HbA1c and body weight decreased
signiﬁcantly in all groups. Decrease in glycemic pa-
rameters tended to be smaller in patients with BMI
o22.5 kg/m2, while that of body weight was larger in
patients with higher BMI. Furthermore, luseogliﬂozin
was especially beneﬁcial in patients with higher BMI843
Clinical Therapeuticsin terms of metabolic abnormalities, including insulin
secretion and hypertension. Luseogliﬂozin exhibited a
favorable and similar safety proﬁle over 52 weeks in
all groups. This agent can be an effective and well-
tolerated therapeutic option in patients with a wide
range of BMI levels, and it may be more beneﬁcial
in patients with higher BMI. (Clin Ther. 2016;38:843–
862) & 2016 The Authors. Published by Elsevier HS
Journals, Inc.
Key words: body mass index, Japanese, luseogli-
ﬂozin, obesity, sodium-glucose cotransporter-2, type 2
diabetes mellitus.
INTRODUCTION
The association of obesity with diabetes mellitus has
been well established. Obesity causes insulin resist-
ance, resulting in the excessive secretion of insulin in
β-cells and subsequent β-cell dysfunction, which leads
to the onset of diabetes mellitus. In many countries,
the prevalence of diabetes mellitus and the number of
individuals with obesity continue to increase, causing
a global health issue. According to recent reports, the
global prevalence of diabetes mellitus was 382 million
people in 2013.1 The world population of overweight
(body mass index [BMI] Z25 to o30 kg/m2) and
obese (BMI Z30 kg/m2) people, as deﬁned by the
World Health Organization,2 was 2.1 billion in
2013.3 Previously, the typical Japanese patient with
type 2 diabetes mellitus (T2DM) tended to be thin
with a relative dysfunction in insulin secretion.
However, the mean BMI of Japanese patients with
T2DM has increased and was 24.9 kg/m2 in 2012.4
According to the Japan Society for the Study of
Obesity, the normal BMI range for the Japanese
population is Z18.5 to o25 kg/m2 while those with
BMI Z25 kg/m2 are considered obese.5 Based on this
classiﬁcation, one half of all Japanese patients with
T2DM are obese. Obesity is becoming more common
in individuals with diabetes mellitus, in the United
States as well.6,7 Obesity should therefore be consid-
ered when developing an effective, efﬁcient, and safe
strategy for the treatment of patients with T2DM.
Although various oral hypoglycemic agents
(OHAs) are currently used after conducting base
diet/exercise therapy, a number of patients continue
to have uncontrollable blood glucose levels and body
weight. There are also legitimate concerns about the
use of OHAs in the treatment of T2DM and the844development of obesity. Insulin or sulfonylureas often
cause body weight gain, and the excess insulin
secretion brought about by these agents may even-
tually cause a decrease in β cells.8 Moreover, the use
of agents that increase insulin secretion may not be
as efﬁcient because obesity causes insulin resistance.
Thus, there is a need for treatment options that
help control not only blood glucose but also body
weight.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors
have emerged as a new class of OHAs, which act by
inhibiting renal glucose reabsorption mediated by
SGLT2 in the proximal renal tubule, thereby increasing
urinary glucose excretion and reducing blood glucose
levels.9 In addition, these agents are associated with
caloric loss, resulting in weight loss as well as a
reduction in blood pressure and triglyceride levels.9,10
Luseogliﬂozin, a highly selective SGLT2 inhibitor,11,12
was developed by Taisho Pharmaceutical Co., Ltd., in
Japan and was approved for the treatment of T2DM
in April 2013. The clinical dose of luseogliﬂozin (2.5
mg daily) is the lowest among the SGLT2 inhibitors
currently available on the market. Another key feature
of luseogliﬂozin is that it is well distributed to the
target site, the renal cortex, where SGLT2 is ex-
pressed.13 When administered as monotherapy or in
combination with other OHAs in a series of Phase III
trials, luseogliﬂozin was associated with signiﬁcant
reductions in glycosylated hemoglobin (HbA1c) levels
and body weight and was accompanied by improve-
ments in blood pressure and lipid parameters.14–17
Luseogliﬂozin thus seems to represent an attractive
therapeutic option, especially for the treatment of
T2DM in patients with obesity. However, the inﬂu-
ence of obesity levels on the efﬁcacy and safety of
luseogliﬂozin remains unclear, as these earlier clinical
trials included both patients with obesity and of
normal body weight. Therefore, for the effective and
proper usage of luseogliﬂozin, a pooled analysis of four
52-week Phase III trials in Japanese patients with T2DM
was conducted to investigate the efﬁcacy and safety of
luseogliﬂozin in these patients stratiﬁed according to
baseline BMI.PATIENTS AND METHODS
Study Design
This was a pooled analysis of Japanese patients
with T2DM taking luseogliﬂozin 2.5 mg daily. AmongVolume 38 Number 4
S. Sakai et al.all clinical trials of luseogliﬂozin, four 52-week, multi-
center, Phase III studies were selected and included in
this analysis from the following perspectives: studies
whose design and patient population are similar to each
other; 52-week Phase III studies that are regarded as
being able to examine the efﬁcacy and safety compara-
tively close to clinical practice. These studies were
conducted between May 2011 and October 2012 and
were registered with the Japan Pharmaceutical Informa-
tion Center (see Supplemental Table I in the online
version at http://dx.doi.org/10.1016/j.clinthera.2016.01.
017). These 4 studies evaluated the following: (1) the
combination study with luseogliﬂozin and glimepiride
(TS071-03-1, JapicCTI-111507)15; (2) a combination
study with luseogliﬂozin and another OHA (biguanides,
dipeptidyl peptidase-4 inhibitors, thiazolidinediones,
glinides, or α-glucosidase inhibitors) (TS071-03-2,
JapicCTI-111508)15; (3) a monotherapy study with
luseogliﬂozin (TS071-03-3, JapicCTI-111509)16; and
(4) a study of luseogliﬂozin in patients with moderate
renal impairment (TS071-03-4, JapicCTI-111543).17
The design of each study and the study groups
included in this analysis are described in separate
articles.15–17
All 4 studies were designed in accordance with the
Japanese guidelines for clinical evaluation of OHAs
and their long-term treatment.18–20 The studies were
conducted with the approval of the ethics committee
of each participating study site, in accordance with the
principles enunciated in the Declaration of Helsinki,
and were consistent with Japanese Good Clinical
Practice and all applicable regulatory requirements.
Patient Population
The study population included in this pooled
analysis comprised patients with T2DM (diagnosed
based on the Japan Diabetes Society [JDS] diagnostic
criteria21) with age Z20 years, with HbA1c levels
Z6.9% tor10.5%, and who underwentZ8 weeks of
regular diet therapy before study entry (at week 4).
Exclusion criteria included: patients with uncontroll-
able blood pressure4170/100 mm Hg; those who had
received insulin within 8 weeks before study entry;
those with a urinary tract or genital infection or dysuria;
those with a clinically apparent hepatic disorder; or
those with alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) elevations 2.5 times higher than
the upper limit of normal. The details of these 4 studies,
including inclusion and exclusion criteria, are describedApril 2016in the supplemental materials of a previously published
article.17
Interventions
Luseogliﬂozin 2.5 mg daily was orally administered
to all patients before breakfast (once daily) for 52 weeks.
The dosage was allowed to be increased to 5 mg daily
after week 24 in patients with HbA1c levelsZ7.4% at
both weeks 16 and 20. All patients were maintained
on diet therapy to ensure a consistent caloric intake
during the entire study period (weeks –4 to 52).
Patients were to continue exercise therapy if it was
prescribed before study entry to ensure a consistent
exercise regime, whereas it was not mandatory in
those who had not been prescribed exercise therapy
before the study entry. In addition, all patients were
prohibited from taking insulins, nontopical cortico-
steroids, mazindol, Chinese medicines that could
inﬂuence body weight, or OHAs other than those
coadministered as speciﬁed in each study protocol. In
principle, modiﬁcation of the dosage of coadminis-
tered OHAs was not allowed during the entire study
period. Although patients were permitted to remain
on any lipid-lowering, antihypertensive, or diuretic
agent that they had received before study entry, they
were not allowed to change their drugs or daily dose
during the entire study period.
Assessments
In the pooled analyses, the changes in HbA1c,
fasting plasma glucose (FPG), and body weight were
evaluated; other efﬁcacy variables included fasting
insulin, blood pressure, and lipid proﬁle from baseline
(week 0) to week 52. The safety analysis included the
incidence of adverse events (AEs), changes in labora-
tory parameters, and vital signs. The details of the
assessments are described separately.17
Statistical Analysis
For the pooled analysis, the efﬁcacy and safety
analyses included the full analysis set (FAS) and the
safety analysis set (SAS) of each study, respectively.
The FAS (or SAS) included all patients who received at
least 1 dose of the study drug and for whom efﬁcacy
(or safety) variables were observed and measured at
least once after receiving the study drug, respectively.
Patients who were randomized to the placebo group in
the FAS and SAS (in TS071-03-1 and TS071-03-4
studies) were excluded; this population was deﬁned as845
Clinical Therapeuticsthe pooled analysis set (see Supplemental Figures 1A
and 1B in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.01.017).
In the present pooled analysis, the outcomes of
efﬁcacy and safety were evaluated among the groups
of patients stratiﬁed by baseline BMI. Patients were
divided into 5 groups based on their baseline
BMI (kg/m2) levels: 1) low-to-medium (BMI o 22.5),
2) medium (BMI Z 22.5 to o 25), 3) high-level 1
(BMIZ 25 too 27.5), 4) high-level 2 (BMIZ 27.5 to
o 30), and 5) very-high (BMI Z 30). In addition, the
changes in HbA1c levels were evaluated in a subpopu-
lation of patients with a baseline HbA1c level Z8%.
Of the patients who completed 52 weeks of treatment,
the proportion of patients with systolic blood pressure
(SBP) Z130 mm Hg, diastolic blood pressure (DBP)
Z80 mm Hg, and triglyceride levels Z150 mg/dL at
weeks 0 and 52 were assessed, respectively.
Basic statistics for each efﬁcacy and safety variable
were calculated at each evaluation visit. The within-group
mean change from baseline for each variable was eval-
uated by using the 1-sample t test (missing or unacceptable
data were not complemented). All HbA1c values meas-
ured in terms of JDS units were converted to their
corresponding National Glycohemoglobin Standardiza-
tion Program (NGSP) units by using the following
validated equation22: HbA1c (NGSP) (%) ¼ 1.02 
JDS (%) þ 0.25%. This calculation allowed for global
comparisons.
All tests were conducted at a 2-sided α level of 0.05.
All analyses were performed by using SAS version 9.2
(SAS Institute Inc., Cary, North Carolina, USA).RESULTS
Demographic Characteristics
Of the 1152 patients enrolled in the 4 Phase III
trials, 1031 Japanese patients with T2DM were
included in this pooled analysis (see Supplemental
Figure 1A in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.01.017). The patients were
stratiﬁed into 5 BMI groups as follows: (1) low-to-
medium, n ¼ 222; (2) medium, n ¼ 270; (3) high-level 1,
n ¼ 262; (4) high-level 2, n ¼ 142; and (5) very-high,
n ¼ 135. The mean HbA1c levels were 7.74%, 7.88%,
7.79%, 7.85%, and 8.02% ranked in order from the
low-to-medium group to the very-high group, res-
pectively (Table I). The mean values of patient age in
each group ranged from 53.3 to 63.9 years, and those for846duration of diabetes ranged from 5.1 to 7.8 years. The
proportion of patients whose baseline estimated
glomerular ﬁltrationrate (eGFR) was r60 mL/min/
1.73m2 was r20% in all groups and those who had
at least 1 diabetic complication ranged from 29.8% to
45.2%. The proportion of patients who completed the
52-week treatment was similar between groups (84.2%,
91.9%, 95.0%, 92.3%, and 93.3%, respectively).
Adherence to prescribed drugs and diet/exercise therapy
throughout the treatment period was conﬁrmed in the
majority of patients.
Efficacy Outcomes
Glycemic Outcomes
After initiation of treatment with luseogliﬂozin,
HbA1c levels decreased signiﬁcantly from baseline to
week 2 (ﬁrst visit) in all groups. This signiﬁcant
decrease was sustained in all groups up to the treat-
ment end period of 52 weeks (Figure 1A). The
decreases in HbA1c at week 52 from baseline were
signiﬁcant in all groups. The mean changes in HbA1c
were –0.37%, –0.59%, –0.53%, –0.60%, and
–0.71% for the low-to-medium, medium, high-level 1,
high-level 2, and very-high groups, respectively (all
groups, P o 0.001 vs baseline) (Table II). Similarly,
FPG levels were signiﬁcantly decreased compared with
baseline from week 2 onward in all groups, and this
signiﬁcant decrease was sustained over time until week
52 (Figure 1B). The mean changes in FPG were –14.5,
–19.9, –18.4, –18.6, and –20.4 mg/dL, respectively (all
groups, Po 0.001 vs baseline; Table II). The reduction
in glycemic parameters tended to be slightly lower in
the low-to-medium group.
In the subgroup analysis, the change in HbA1c at
week 52 in patients with baseline HbA1c levels
Z8% was –0.91%, –1.02%, –1.06%, –1.08%, and
–1.18%, respectively (all groups, P o 0.001 vs base-
line) (Figure 2). The decrease in HbA1c was greater in
the patients with baseline HbA1c levels Z8%
compared with the overall decrease in each group.
Body Weight Outcomes
Body weight signiﬁcantly decreased compared with
baseline from week 2 onward, and the decrease was
sustained over time until week 52 in all groups;
a relatively rapid decrease was observed during the
initial phase (up to about week 8), and it became
slower thereafter (Figure 1C). After the initial phase,
the decrease in body weight in the groups with lowerVolume 38 Number 4
Table I. Demographic and baseline characteristics of patients in the pooled analysis population.*
Characteristic
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
(o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
No. of patients at baseline 222 270 262 142 135
Age, mean (SD), y 63.9 (9.3) 61.8 (9.9) 60.9 (10.3) 58.2 (10.5) 53.3 (10.8)
Male 155 (69.8) 199 (73.7) 185 (70.6) 85 (59.9) 90 (66.7)
Duration of diabetes, mean (SD), y 7.8 (6.7) 7.3 (6.2)† 6.1 (5.7)‡ 5.2 (5.1) 5.1 (4.7)¶
Body weight, mean (SD), kg 54.94 (6.76) 64.07 (7.51) 69.26 (7.94) 75.12 (8.58) 89.50 (12.47)
BMI, mean (SD), kg/m2 20.79 (1.26) 23.87 (0.70) 26.08 (0.68) 28.55 (0.72) 33.08 (3.24)
HbA1c, mean (SD), % 7.74 (0.76) 7.88 (0.76) 7.79 (0.72) 7.85 (0.77) 8.02 (0.88)
HbA1c
o7% 14 (6.3) 7 (2.6) 11 (4.2) 4 (2.8) 7 (5.2)
Z7% to o8% 145 (65.3) 169 (62.6) 168 (64.1) 89 (62.7) 71 (52.6)
Z8% to o9% 42 (18.9) 63 (23.3) 57 (21.8) 36 (25.4) 37 (27.4)
Z9% 21 (9.5) 31 (11.5) 26 (9.9) 13 (9.2) 20 (14.8)
FPG, mean (SD), mg/dL 141.3 (29.3) 146.2 (29.1) 144.3 (26.3) 144.3 (28.9) 147.1 (29.5)
Glycoalbumin, mean (SD), % 21.28 (3.67) 20.93 (3.36) 19.93 (3.06) 19.59 (2.94) 19.38 (3.03)
Fasting insulin, mean (SD), μU/mL 4.05 (2.20) 6.31 (3.31) 7.84 (4.43) 9.60 (5.56) 13.57 (7.63)
Fasting CPR, mean (SD), ng/mL 0.96 (0.38) 1.26 (0.48) 1.46 (0.57) 1.62 (0.59) 1.98 (0.81)
CPI, mean (SD) 0.70 (0.29) 0.88 (0.37) 1.03 (0.44) 1.15 (0.46) 1.38 (0.54)
eGFR, mean (SD), mL/min/1.73m2 78.6 (18.5) 78.2 (18.5) 79.0 (18.0) 78.0 (19.5) 85.5 (22.7)
eGFR
o60 mL/min/1.73m2 38 (17.1) 45 (16.7) 37 (14.1) 24 (16.9) 14 (10.4)
Z60 to o90 mL/min/1.73m2 127 (57.2) 151 (55.9) 166 (63.4) 84 (59.2) 70 (51.9)
Z90 mL/min/1.73m2 57 (25.7) 74 (27.4) 59 (22.5) 34 (23.9) 51 (37.8)
SBP, mean (SD), mm Hg 122.6 (15.4) 128.2 (14.7) 128.7 (14.2) 133.5 (13.1) 132.2 (13.3)
DBP, mean (SD), mm Hg 70.9 (9.6) 76.0 (9.3) 75.8 (9.7) 78.2 (9.9) 80.2 (9.6)
No use of HA 62 (27.9) 76 (28.1) 90 (34.4) 37 (26.1) 42 (31.1)
Concomitant HA 160 (72.1) 194 (71.9) 172 (65.6) 105 (73.9) 93 (68.9)
Met 13 (5.9) 39 (14.4) 38 (14.5) 26 (18.3) 18 (13.3)
SU 54 (24.3) 66 (24.4) 45 (17.2) 19 (13.4) 21 (15.6)
TZD 16 (7.2) 20 (7.4) 28 (10.7) 20 (14.1) 22 (16.3)
DPP4i 35 (15.8) 31 (11.5) 34 (13.0) 22 (15.5) 13 (9.6)
Glinide 20 (9.0) 13 (4.8) 14 (5.3) 8 (5.6) 10 (7.4)
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Table I. (continued).
Characteristic
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
(o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
α-GI 30 (13.5) 39 (14.4) 24 (9.2) 15 (10.6) 15 (11.1)
GLP-1 RAs 0 0 0 0 0
Insulin 0 0 0 0 0
History of HA use 72 (32.4) 106 (39.3) 93 (35.5) 49 (34.5) 50 (37.0)
Use of Concomitant lipid-lowering agents 106 (47.7) 136 (50.4) 129 (49.2) 80 (56.3) 62 (45.9)
Use of Concomitant diuretics 16 (7.2) 26 (9.6) 28 (10.7) 19 (13.4) 22 (16.3)
Thiazides 12 (5.4) 20 (7.4) 20 (7.6) 16 (11.3) 18 (13.3)
Loop diuretics 1 (0.5) 3 (1.1) 3 (1.1) 2 (1.4) 1 (0.7)
Use of Concomitant antihypertensive agents 88 (39.6) 134 (49.6) 139 (53.1) 92 (64.8) 83 (61.5)
ARBs 62 (27.9) 107 (39.6) 102 (38.9) 68 (47.9) 64 (47.4)
ACE inhibitors 4 (1.8) 8 (3.0) 14 (5.3) 11 (7.7) 9 (6.7)
Diabetic complications 87 (39.2) 110 (40.7) 78 (29.8) 43 (30.3) 61 (45.2)
Diabetic nephropathy 53 (23.9) 71 (26.3) 54 (20.6) 31 (21.8) 44 (32.6)
Diabetic neuropathy 31 (14.0) 39 (14.4) 19 (7.3) 5 (3.5) 14 (10.4)
Diabetic retinopathy 29 (13.1) 37 (13.7) 20 (7.6) 13 (9.2) 9 (6.7)
Nondiabetic complications — — — — —
Hypertension 92 (41.4) 149 (55.2) 161 (61.5) 96 (67.6) 95 (70.4)
Dyslipidemia 145 (65.3) 206 (76.3) 211 (80.5) 112 (78.9) 105 (77.8)
Renal disease 33 (14.9) 26 (9.6) 31 (11.8) 14 (9.9) 11 (8.1)
Cardiac disease 26 (11.7) 38 (14.1) 25 (9.5) 21 (14.8) 13 (9.6)
Endocrine disease 1 (0.5) 9 (3.3) 9 (3.4) 5 (3.5) 0
Hepatobiliary disease 64 (28.8) 90 (33.3) 106 (40.5) 77 (54.2) 77 (57.0)
Gastrointestinal disease 70 (31.5) 104 (38.5) 93 (35.5) 27 (19.0) 34 (25.2)
α-GI ¼ α-glucosidase inhibitor; ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CPI ¼ C-peptide
immunoreactivity index; CPR ¼ C-peptide immunoreactivity; DBP ¼ diastolic blood pressure; DPP4i ¼ dipeptidyl peptidase-4 inhibitor; eGFR ¼ estimated glomerular
ﬁltration rate; FPG ¼ fasting plasma glucose; HA ¼ hypoglycemic agent; HbA1c ¼ glycosylated hemoglobin; GLP-1 RAs ¼ glucagon-like peptide-1 receptor agonists;
Met ¼ metformin; SBP ¼ systolic blood pressure; SU ¼ sulfonylurea; TZD ¼ thiazolidinedione.
*Unless indicated otherwise, values are given as N (%).
†n ¼ 268.
‡n ¼ 261.
¶n ¼ 134.
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Figure 1. Changes over 52 weeks in (A) HbA1c,
(B) FPG, and (C) body weight for all
BMI groups who received luseogliflozin.
Panel C is change from baseline. Data
are presented as mean ± 95% CI.
BMI = body mass index; CI=confidence
interval; FPG = fasting plasma glucose;
HbA1c = glycosylated hemoglobin.
S. Sakai et al.BMI was smaller, whereas the decrease in the groups
with higher BMI groups was larger and consistent.
The mean change in body weight at week 52 from
baseline was –1.85, –2.40, –2.40, –2.70, and –3.54
kg, respectively (all groups, P o 0.001 vs baseline)
(Table II). The reduction in body weight at week 52
tended to be greater with BMI, especially in the very-
high BMI group. The percent change from baseline in
body weight ranged from –3.35% to –4.03% in the
low-to-medium to the very-high groups.April 2016Other Efficacy Outcomes
Levels of glycoalbumin, fasting insulin, and fast-
ing C-peptide immunoreactivity were signiﬁcantly
decreased at week 52 from baseline in all groups.
Although homeostatic model assessment of β-cell
function signiﬁcantly decreased in the low-to-medium
and medium groups, there was no clear change in the
other groups (Table II).
Blood Pressure
At week 52, both SBP and DBP were signiﬁcantly
decreased from baseline in all groups (Figure 3,
Table II). The reduction in blood pressure seemed to
be greater in the groups with higher BMI levels; the
decline appeared to be rapid during the initial phase
(up to 2 or 4 weeks) in all groups other than the low-
to-medium group (see Supplemental Figure 2 in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2016.01.017).
The proportion of patients with SBPZ130 mm Hg
and DBP Z80 mm Hg at week 52 was decreased
compared with week 0 in all groups, and the decrease
of the proportion of these patients was larger in the
groups with higher BMI levels (see Supplemental
Figure 3 in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.01.017). In addition, the
subgroup analysis of baseline SBP showed that the
degree of the SBP decrease in patients with baseline
Z130 mm Hg was greater than that in patients with
SBP o130 mm Hg for all BMI groups; the changes at
week 52 in patients with SBP Z130 mm Hg were
–10.3, –9.9, –10.7, –9.7, and –9.3 mm Hg, respectively
in the low-to-medium, medium, high-level 1, high-level 2,
and very-high groups, showing a signiﬁcant decrease
from baseline (all groups, Po 0.001) (see Supplemental
Table II in the online version at http://dx.doi.org/10.
1016/j.clinthera.2016.01.017).
Lipid Parameters, Hepatic Parameters, and Uric
Acid
Triglyceride levels tended to be decreased at week
52 from baseline in all groups (Figure 3, Table II). The
mean changes in triglyceride were –9.3 mg/dL in the
low-to-medium group, and they ranged from –24.1 to
–13.6 mg/dL in the other groups. The proportion of
patients with triglyceride levels Z150 mg/dL was
decreased at week 52 from week 0 in all groups
(see Supplemental Figure 3 in the online version at
http://dx.doi.org/10.1016/j.clinthera.2016.01.017).849
Table II. Changes in efficacy parameters from baseline to week 52 for all BMI groups who received luseogliflozin.*
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
Variable (o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
No. of patients at baseline 222 270 262 142 135
No. of patients at week 52 187 248 249 131 126
HbA1c, % At baseline 7.74 (0.76) 7.88 (0.76) 7.79 (0.72) 7.85 (0.77) 8.02 (0.88)
Changes at week 52 –0.37 (–0.46 to –0.28)† –0.59 (–0.66 to –0.51)† –0.53 (–0.62 to –0.45)† –0.60 (–0.72 to –0.49)† –0.71 (–0.84 to –0.58)†
FPG, mg/dL At baseline 141.3 (29.3) 146.2 (29.1) 144.3 (26.3) 144.3 (28.9) 147.1 (29.5)
Changes at week 52 –14.5 (–17.8 to –11.1)† –19.9 (–22.9 to –16.9)† –18.4 (–21.3 to –15.6)† –18.6 (–22.4 to –14.7)† –20.4 (–24.8 to –15.9)†
Body weight, kg At baseline 54.94 (6.76) 64.07 (7.51) 69.26 (7.94) 75.12 (8.58) 89.50 (12.47)
Changes at week 52 –1.85 (–2.12 to –1.59)† –2.40 (–2.65 to –2.16)† –2.40 (–2.66 to –2.13)† –2.70 (–3.13 to –2.27)† –3.54 (–4.09 to –2.99)†
% change at week 52 –3.35 (–3.83 to –2.86)† –3.76 (–4.14 to –3.38)† –3.51 (–3.89 to –3.12)† –3.62 (–4.19 to –3.05)† –4.03 (–4.64 to –3.42)†
Glycoalbumin, % At baseline 21.28 (3.67) 20.93 (3.36) 19.93 (3.06) 19.59 (2.94) 19.38 (3.03)
Changes at week 52 –1.86 (–2.19 to –1.54)† –2.58 (–2.84 to –2.32)† –2.29 (–2.56 to –2.03)† –2.39 (–2.76 to –2.02)† –2.67 (–3.06 to –2.29)†
Fasting insulin, μU/mL At baseline 4.05 (2.20) 6.31 (3.31) 7.84 (4.43) 9.60 (5.56) 13.57 (7.63)
Changes at week 52 –0.92 (–1.17 to –0.68)† –1.68 (–2.00 to –1.36)† –1.70 (–2.05 to –1.36)† –2.06 (–2.72 to –1.41)† –3.28 (–4.10 to –2.45)†
Fasting CPR, ng/mL At baseline 0.96 (0.38) 1.26 (0.48) 1.46 (0.57) 1.62 (0.59) 1.98 (0.81)
Changes at week 52 –0.14 (–0.18 to –0.10)† –0.22 (–0.26 to –0.18)† –0.26 (–0.31 to –0.22)† –0.31 (–0.37 to –0.24)† –0.30 (–0.38 to –0.22)†
HOMA-β, % At baseline 21.2 (16.7) 30.1 (19.0) 37.4 (26.4) 47.9 (36.9) 63.7 (38.7)
Changes at week 52 –1.9 (–3.2 to –0.7)‡ –2.5 (–4.4 to –0.5) ‡ –0.8 (–2.8 to 1.3) 0.2 (–5.2 to 5.7) –2.0 (–7.4 to 3.3)
CPI At baseline 0.70 (0.29) 0.88 (0.37) 1.03 (0.44) 1.15 (0.46) 1.38 (0.54)
Changes at week 52 –0.04 (–0.07 to –0.02)‡ –0.06 (–0.09 to –0.03)† –0.08 (–0.11 to –0.05)† –0.09 (–0.14 to –0.03)‡,¶ –0.04 (–0.10 to 0.02)
ALT, IU/L/37°C At baseline 20.8 (11.6) 25.0 (13.3) 29.1 (17.3) 32.8 (19.3) 38.7 (20.5)
Changes at week 52 –1.6 (–2.9 to –0.2) ‡ –3.9 (–4.9 to –2.9)† –6.0 (–7.6 to –4.4)† –7.5 (–10.3 to –4.8)† –9.0 (–11.7 to –6.4)†
AST, IU/L/37°C At baseline 22.7 (6.8) 24.4 (8.9) 26.7 (10.8) 28.0 (10.7) 31.3 (13.3)
Changes at week 52 0.3 (–0.6 to 1.2) –1.2 (–2.0 to –0.4) ‡ –2.7 (–3.8 to –1.6)† –3.0 (–4.7 to –1.3)† –4.7 (–6.3 to –3.1)†
γ-GTP, IU/L/37°C At baseline 33.3 (29.1) 46.9 (49.6) 44.5 (35.1) 49.4 (36.4) 60.2 (60.6)
Changes at week 52 –5.3 (–7.8 to –2.8)† –9.4 (–13.5 to –5.3)† –8.3 (–11.0 to –5.7)† –8.5 (–11.7 to –5.4)† –8.8 (–12.9 to –4.8)†
Triglyceride, mg/dL At baseline 105.6 (71.3) 144.4 (99.5) 149.8 (105.9) 164.4 (104.2) 167.6 (109.8)
Changes at week 52 –9.3 (–18.4 to –0.2)‡ –24.1 (–33.1 to –15.0)† –13.6 (–28.2 to 1.0) –18.1 (–38.0 to 1.8) –21.2 (–32.4 to –10.0)†
HDL-C, mg/dL At baseline 63.8 (15.6) 56.9 (15.5) 54.7 (13.2) 54.4 (13.6) 53.5 (14.0)
Changes at week 52 6.6 (5.2 to 7.9)† 5.7 (4.6 to 6.8)† 4.8 (3.8 to 5.8)† 4.8 (3.3 to 6.2)† 2.9 (1.6 to 4.1)†
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Table II. (continued).
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
Variable (o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
LDL-C, mg/dL At baseline 113.5 (27.8) 113.5 (28.0) 120.0 (31.0) 119.4 (26.9) 119.8 (28.7)
Changes at week 52 2.1 (–0.8 to 5.1) 2.3 (–0.1 to 4.7) –1.1 (–3.9 to 1.7) 3.1 (–0.8 to 7.0) 1.8 (–1.9 to 5.6)
LDL-C/HDL-C At baseline 1.88 (0.65) 2.14 (0.76) 2.33 (0.84) 2.35 (0.87) 2.37 (0.79)
Changes at week 52 –0.13 (–0.19 to –0.08)† –0.15 (–0.20 to –0.10)† –0.20 (–0.25 to –0.14)† –0.12 (–0.20 to –0.05) ‡ –0.06 (–0.14 to 0.02)
Non–HDL-C, mg/dL At baseline 129.1 (30.6) 135.3 (31.3) 142.1 (36.8) 144.3 (31.8) 144.0 (33.4)
Changes at week 52 –1.5 (–4.7 to 1.8) –3.6 (–6.3 to –0.9)‡ –5.0 (–8.2 to –1.7)‡ –2.0 (–6.1 to 2.0) –2.4 (–6.4 to 1.6)
Adiponectin, μg/mL At baseline 9.50 (5.63) 7.82 (5.01) 7.18 (4.02) 7.48 (6.68) 7.02 (4.93)
Changes at week 52 1.38 (1.01 to 1.76)† 1.00 (0.75 to 1.26)† 0.76 (0.55 to 0.96)† 0.75 (0.49 to 1.01)† 0.52 (0.18 to 0.86)‡
Leptin, ng/mL At baseline 4.21 (2.52) 6.12 (3.50) 8.02 (5.28) 10.77 (5.48) 14.64 (7.72)
Changes at week 52 –0.47 (–0.70 to –0.24)† –0.75 (–1.05 to –0.45)† –0.79 (–1.06 to –0.52)† –1.31 (–1.91 to –0.71)† –1.47 (–2.35 to –0.59)‡
Uric acid, mg/dL At baseline 4.89 (1.25) 5.26 (1.23) 5.42 (1.24) 5.65 (1.39) 5.70 (1.43)
Changes at week 52 –0.34 (–0.45 to –0.23)† –0.37 (–0.48 to –0.26)† –0.50 (–0.62 to –0.39)† –0.60 (–0.78 to –0.43)† –0.57 (–0.72 to –0.42)†
SBP, mm Hg At baseline 122.6 (15.4) 128.2 (14.7) 128.7 (14.2) 133.5 (13.1) 132.2 (13.3)
Changes at week 52 –2.5 (–4.3 to –0.6) ‡ –4.2 (–5.8 to –2.6)† –5.3 (–6.9 to –3.6)† –6.5 (–8.6 to –4.5)† –5.7 (–7.9 to –3.4)†
DBP, mm Hg At baseline 70.9 (9.6) 76.0 (9.3) 75.8 (9.7) 78.2 (9.9) 80.2 (9.6)
Changes at week 52 –1.9 (–3.1 to –0.7) ‡ –2.6 (–3.7 to –1.6)† –2.3 (–3.4 to –1.2)† –3.5 (–5.1 to –2.0)† –3.5 (–5.1 to –1.8)†
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; BMI=body mass index; CI=conﬁdence interval; CPI ¼ C-peptide immunoreactivity index; CPR ¼
C-peptide immunoreactivity; DBP ¼ diastolic blood pressure; FPG ¼ fasting plasma glucose; γ-GTP ¼ γ-glutamyl transpeptidase; HbA1c ¼ glycosylated hemoglobin;
HDL-C = high density lipoprotein cholesterol; HOMA-β ¼ homeostatic model assessment of β-cell function; LDL-C = low density lipoprotein cholesterol; SBP ¼
systolic blood pressure.
*Unless indicated otherwise, data are given as mean (SD) for baseline values and as mean (95% CI) for changes and % change at week 52.
†P o 0.001, versus baseline, 1-sample t test.
‡P o 0.05, versus baseline, 1-sample t test.
¶n ¼ 130.
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Figure 2. Changes in HbA1c at week 52 in
patients with baseline HbA1c levels
Z8% for all BMI groups who received
luseogliflozin. *P o 0.001 versus
baseline (1-sample t test). Data are
presented as mean ± 95% CI. BMI ¼
body mass index; BL ¼ baseline;
CI ¼ confidence interval; HbA1c ¼
glycosylated hemoglobin.
Clinical TherapeuticsThe proportion of patients with baseline
triglyceride levels Z150 mg/dL was higher in the
groups with higher BMI levels at baseline, and the
52-week administration of luseogliﬂozin seemed to
reduce the proportion of patients with high trigly-
ceride levels.
Leptin levels also decreased in all groups, and the
decrease tended to be larger in the groups with higher
BMI levels. High density lipoprotein cholesterol
(HDL-C) and adiponectin levels signiﬁcantly increased
in all groups; however, the increase tended to be larger
in the groups with lower BMI levels. Although the
levels of low density lipoprotein cholesterol (LDL-C)/
HDL-C and non–HDL-C tended to decrease in all
groups, the decrease was not signiﬁcant in some
groups. No clear changes were seen in LDL-C in
any group (Table II).
At week 52, AST and ALT levels were signiﬁcantly
decreased from baseline in all groups, other than AST
in the low-to-medium group. The decrease was greater
in the groups with higher BMI levels (Figure 3,
Table II) and was sustained throughout the study
(see Supplemental Figure 2 in the online version at
http://dx.doi.org/10.1016/j.clinthera.2016.01.017).
Uric acid levels signiﬁcantly decreased in all groups,
and the decrease appeared to be greater in the groups
with higher BMI levels (Figure 3, Table II).852Safety Outcomes
Adverse Events
The incidence of AEs during the 52 weeks of
treatment with luseogliﬂozin was similar across
groups (Table III), and the majority of AEs reported
were mild in severity and manageable. No trends were
observed in the incidence of serious AEs based on BMI
levels. Although the incidence of AEs that led to
discontinuation of the study drug tended to be
slightly higher in the groups with lower BMI levels,
the details of these AEs were not speciﬁc.
AEs of Special Interest
Table III summarizes the incidence of AEs of
special interest during 52 weeks of treatment with
luseogliﬂozin. The incidence of hypoglycemia was
similar across all groups, and the majority of the
hypoglycemic episodes were mild in severity, with no
severe or serious events of hypoglycemia reported.
Moderate hypoglycemia developed in 2 patients; 1 in
the low-to-medium group had received a sulfonylurea
concomitantly, and the other in the high-level 1 group
had received luseogliﬂozin monotherapy. In both
cases, the assistance of another person was not
necessary, and both patients continued with luseogli-
ﬂozin therapy.
The incidence of AEs related to cardiovascular
disorders was similar across all groups. Serious AEs
related to cardiovascular disorders were observed in 4,
4, 1, 2, and 2 patients in the low-to-medium, medium,
high-level 1, high-level 2, and very-high groups, respec-
tively. Myocardial infarction or acute myocardial in-
farction was observed in 3 patients (1 patient each in
the low-to-medium, high-level 2, and very-high groups).
Cerebral infarction was observed in 4 patients (2 patients
each in the low-to-medium and medium groups).
The incidence of urinary tract infections and genital
infections was similar across groups, and the majority
of those infections were mild in severity. The incidence
of these events tended to be higher in female patients
compared with male patients throughout all groups
(Table III).
AEs related to volume depletion and hypotension
were similarly low in incidence across all groups, with
no serious or severe AEs noted. There were no clear
differences in the incidence of AEs related to increases
in plasma ketone bodies between the groups. All of the
events reported were mild, and most of them were
reversible. The incidence of AEs related to boneVolume 38 Number 4
Low-to-medium Medium High-level 1 High-level 2 Very-high
BMI groups, kg/m2 (<22.5) (<22.5)(≥22.5 (≥22.5(≥25 (≥25(≥27.5 (≥27.5(≥30) (≥30)
to <25) to <25)to <27.5) to <27.5)to <30) to <30)
187 248 249 187 248 249131 126 131 126
Low-to-medium Medium High-level 1 High-level 2 Very-high
N (at week 52)
−2.5
−1.9
−2.6
−2.3
−3.5 −3.5
−4.2
−5.3
−6.5
−5.7
0
−2
−4
−6
−8
−10
−9.3
−24.1
−13.6
−18.1 −21.2
−1.2
−2.7
−3.0
−4.7
−0.57
−0.60
−0.50
−0.37−0.34
0.0
−0.2
−0.4
−0.6
−0.8
−1.0−9.0
−7.5
−6.0
−3.9
−1.6
0
−10
−20
−30
−40
−50
0
−2
−4
−6
−8
−10
−12
−14
2
0
−2
−4
−6
−8
0
−1
−2
−3
−4
−5
−6
*
* *
*
*
A B
C D
E F
C
ha
ng
e 
in
 S
B
P
 (
m
m
 H
g)
C
ha
ng
e 
in
 D
B
P
 (
m
m
 H
g)
C
ha
ng
e 
in
 T
ri
gl
yc
er
id
e 
(m
g/
dL
)
C
ha
ng
e 
in
 U
ri
c 
A
ci
d 
(m
g/
dL
)
C
ha
ng
e 
in
 A
LT
 (
IU
/L
/3
7°
C
)
C
ha
ng
e 
in
 A
ST
 (
IU
/L
/3
7°
C
) 0.3
Figure 3. Changes in (A) SBP, (B) DBP, (C) Triglyceride, (D) AST, (E) ALT, and (F) Uric acid at week 52 for all
BMI groups who received luseogliflozin. *P o 0.05, †P o 0.001 versus baseline (1-sample t test).
Data are presented as mean ± 95% CI. ALT ¼ alanine aminotransferase; AST ¼ aspartate
aminotransferase; BMI ¼ body mass index; CI ¼ confidence interval; DBP ¼ diastolic blood
pressure; SBP ¼ systolic blood pressure
S. Sakai et al.metabolism (including fractures) was similar across
groups, and none of the AEs reported was considered
to be related to the study drug.
Laboratory Parameters
Hemoglobin, hematocrit, and blood urea nitrogen
levels increased signiﬁcantly from baseline in all groups
(Table IV). There were no marked between-group
differences in changes in these parameters, and the
levels of hemoglobin and hematocrit were seen to be
increased until week 12 and plateaued thereafter in all
groups (for hematocrit, refer to Supplemental Figure 2April 2016in the online version at http://dx.doi.org/10.1016/
j.clinthera.2016.01.017); hemoglobin, data not shown).
The transitions of eGFR changes were similar
across all groups. eGFR decreased transiently in the
initial phase of treatment (at week 2) and then
increased. At week 52, eGFR returned to a level
similar to that at baseline (see Supplemental Figure 2
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2016.01.017). In the very-high group,
while the decrease in eGFR at week 52 from
baseline was signiﬁcant, the degree of observed
change was small (Table IV).853
Table III. AEs reported during 52 weeks of treatment with luseogliflozin for all BMI groups.*
Variable
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
(o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
No. of patients at baseline 222 270 262 142 135
AEs 171 (77.0) 209 (77.4) 194 (74.0) 116 (81.7) 109 (80.7)
Adverse drug reactions 43 (19.4) 58 (21.5) 46 (17.6) 25 (17.6) 26 (19.3)
Deaths† 1 (0.5) 0 1 (0.4) 0 0
Serious AEs‡ 15 (6.8) 24 (8.9) 16 (6.1) 7 (4.9) 6 (4.4)
AEs leading to discontinuation 17 (7.7) 14 (5.2) 8 (3.1) 7 (4.9) 2 (1.5)
Common AEs (observed in Z5% of patients in any group)
Constipation 5 (2.3) 19 (7.0) 8 (3.1) 11 (7.7) 5 (3.7)
Diarrhea 6 (2.7) 3 (1.1) 3 (1.1) 5 (3.5) 7 (5.2)
Nasopharyngitis 60 (27.0) 79 (29.3) 80 (30.5) 42 (29.6) 45 (33.3)
Pharyngitis 6 (2.7) 5 (1.9) 9 (3.4) 8 (5.6) 4 (3.0)
Upper respiratory tract infection 13 (5.9) 19 (7.0) 15 (5.7) 10 (7.0) 12 (8.9)
Increase in urine β2-microglobulin 16 (7.2) 17 (6.3) 10 (3.8) 6 (4.2) 4 (3.0)
Increase in C-reactive protein 16 (7.2) 31 (11.5) 28 (10.7) 10 (7.0) 19 (14.1)
Back pain 7 (3.2) 7 (2.6) 8 (3.1) 7 (4.9) 10 (7.4)
AEs of special interest
Hypoglycemia§ 10 (4.5) 13 (4.8) 9 (3.4) 4 (2.8) 3 (2.2)
AEs related to pollakiuria|| 3 (1.4) 6 (2.2) 12 (4.6) 3 (2.1) 6 (4.4)
AEs related to volume depletion¶ 2 (0.9) 5 (1.9) 4 (1.5) 3 (2.1) 2 (1.5)
Hypotension# 2 (0.9) 2 (0.7) 0 2 (1.4) 2 (1.5)
AEs related to cardiovascular disorders** 13 (5.9) 10 (3.7) 11 (4.2) 5 (3.5) 10 (7.4)
Urinary tract infection†† 5 (2.3) 9 (3.3) 11 (4.2) 6 (4.2) 7 (5.2)
Male‡‡ 1 (0.6) 2 (1.0) 3 (1.6) 0 1 (1.1)
Female§§ 4 (6.0) 7 (9.9) 8 (10.4) 6 (10.5) 6 (13.3)
Urinary tract infection|||| 3 (1.4) 6 (2.2) 4 (1.5) 4 (2.8) 4 (3.0)
Genital infections¶¶ 3 (1.4) 1 (0.4) 2 (0.8) 3 (2.1) 5 (3.7)
Male‡‡ 2 (1.3) 0 0 0 2 (2.2)
Female§§ 1 (1.5) 1 (1.4) 2 (2.6) 3 (5.3) 3 (6.7)
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Table III. (continued).
Variable
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
(o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
AEs related to bone metabolism## 4 (1.8) 8 (3.0) 5 (1.9) 3 (2.1) 2 (1.5)
AEs related to increase in ketone bodies*** 11 (5.0) 8 (3.0) 6 (2.3) 3 (2.1) 4 (3.0)
AEs related to skin disorders††† 20 (9.0) 20 (7.4) 21 (8.0) 9 (6.3) 7 (5.2)
AEs = adverse events; BMI = body mass index.
*Unless indicated otherwise, data are given as N (%).
†Acute myocardial infarction and pancreatic cancer.
‡Including death.
§Decrease in blood glucose, hypoglycemia, and hypoglycemia unawareness.
||Increase in urine volume and pollakiuria.
¶Thirst, decrease in blood potassium, increase in blood urea, uric acid, hematocrit, hemoglobin, red blood cell count, and dehydration.
#Decrease in blood pressure, hypotension, and orthostatic hypotension.
**AEs observed in Z2 patients: angina pectoris, atrial ﬁbrillation, palpitations, increase in blood creatine phosphokinase, and cerebral infarction.
††Including laboratory abnormalities (ie, urinary white blood cell positive, bacterial test positive, and fungal test positive) and others (cystitis, pyelonephritis, urinary
tract infection, bacterial cystitis).
‡‡No. of male patients at baseline: n ¼ 155 (low-to-medium), n ¼ 199 (medium), n ¼ 185 (high-level 1), n ¼ 85 (high-level 2), n ¼ 90 (very-high).
§§No. of female patients at baseline: n ¼ 67 (low-to-medium), n ¼ 71 (medium), n ¼ 77 (high-level 1), n ¼ 57 (high-level 2), n ¼ 45 (very-high).
||||Excluding laboratory abnormalities.
¶¶Candidal balanitis, genital candidiasis, genital herpes, vulvitis, vulvovaginal candidiasis, bacterial vaginosis, and prostatitis.
##Bone fracture, increase in blood parathyroid hormone, and increase in blood phosphate.
***Increase in free fatty acids, increase in blood ketone bodies, urinary ketone body present, ketosis, and metabolic acidosis.
†††Dermatitis, dermatitis allergic, dermatitis contact, drug eruption, eczema, asteatotic eczema, eczema nummular, erythema, heat rash, prurigo, rash, urticaria, and
seborrheic dermatitis.
S
.
S
ak
ai
et
al.
A
p
ril
2
0
1
6
8
5
5
Table IV. Changes in laboratory parameters from baseline to week 52 for all BMI groups who received luseogliflozin.*
BMI Levels, kg/m2
Low-to-medium Medium High-level 1 High-level 2 Very-high
Variable (o22.5) (Z22.5 to o25) (Z25 to o27.5) (Z27.5 to o30) (Z30)
No. of patients at baseline 222 270 262 142 135
No. of patients at week 52 187 248 249 131 126
Hemoglobin, g/dL At baseline 13.34 (1.37) 13.83 (1.31) 13.87 (1.29) 13.75 (1.25) 14.05 (1.25)
Changes at week 52 0.82 (0.71 to 0.93)† 0.84 (0.76 to 0.93)†,‡ 0.79 (0.70 to 0.88)† 0.79 (0.63 to 0.94)† 0.99 (0.88 to 1.09)†
Hematocrit, % At baseline 40.26 (4.12) 41.60 (3.77) 41.76 (3.63) 41.52 (3.52) 42.18 (3.45)
Changes at week 52 2.19 (1.87 to 2.52)† 2.24 (1.99 to 2.49)†,‡ 2.07 (1.80 to 2.34)† 2.05 (1.61 to 2.49)† 2.78 (2.46 to 3.11)†
BUN, mg/dL At baseline 16.00 (4.77) 14.76 (4.00) 14.90 (3.58) 15.11 (4.03) 14.13 (4.27)
Changes at week 52 1.87 (1.36 to 2.37)† 2.79 (2.34 to 3.23)† 1.92 (1.46 to 2.39)† 1.56 (0.96 to 2.17)† 1.00 (0.38 to 1.62)¶
Creatinine, mg/dL At baseline 0.752 (0.206) 0.769 (0.199) 0.753 (0.174) 0.757 (0.196) 0.735 (0.219)
Changes at week 52 0.003 (–0.007 to 0.012) 0.013 (0.003 to 0.023)¶ 0.002 (–0.007 to 0.011) 0.014 (–0.001 to 0.028) 0.017 (0.005 to 0.029)¶
eGFR, mL/min/1.73m2 At baseline 78.6 (18.5) 78.2 (18.5) 79.0 (18.0) 78.0 (19.5) 85.5 (22.7)
Changes at week 52 0.0 (–1.0 to 1.1) –0.8 (–1.8 to 0.2) 0.4 (–0.6 to 1.4) –0.9 (–2.2 to 0.4) –1.5 (–3.1 to 0.0) ¶
Urinary albumin (Cr-corrected),
mg/g Cr
At baseline 88.0 (368.6) 61.0 (306.6) 38.0 (109.5) 62.1 (276.1) 104.5 (449.3)
Changes at week 52 –3.0 (–39.1 to 33.1) 16.3 (–12.6 to 45.3) –3.4 (–16.1 to 9.4) –13.3 (–26.8 to 0.2) –28.7 (–77.7 to 20.3)
Acetoacetic acid, μmol/L At baseline 38.9 (28.0) 34.7 (28.3) 33.4 (23.5) 32.8 (30.3) 31.4 (20.4)
Changes at week 52 21.0 (15.0 to 27.0)† 29.0 (21.4 to 36.7)† 21.9 (15.9 to 27.9)† 16.1 (8.5 to 23.7)† 23.5 (15.5 to 31.5)†
β-hydroxybutyric acid,
μmol/L
At baseline 95.5 (94.8) 79.6 (85.2) 70.3 (61.2) 71.0 (81.5) 66.6 (55.8)
Changes at week 52 52.6 (34.8 to 70.4)† 91.0 (59.6 to 122.5)† 47.3 (31.1 to 63.5)† 40.3 (17.6 to 63.1)† 62.6 (37.2 to 87.9)†
BMI ¼ body mass index; BUN ¼ blood urea nitrogen; CI ¼ conﬁdence interval; Cr ¼ creatinine; eGFR ¼ estimated glomerular ﬁltration rate.
*Unless indicated otherwise, data are given as mean (SD) for baseline values and mean (95% CI) for changes at week 52.
†P o 0.001 versus baseline, 1-sample t test.
‡n ¼ 247.
¶P o 0.05 versus baseline, 1-sample t test.
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S. Sakai et al.Levels of plasma ketone bodies (acetoacetic acid
and β-hydroxybutyric acid) increased signiﬁcantly in
all groups, although the incidence of ketoacidosis
caused by luseogliﬂozin was not reported. There was
no correlation between the mean change in plasma
ketone bodies and BMI levels (Table IV). However,
the high variation in the individual increases in plasma
ketone bodies may have contributed to a high overall
mean value. Based on the median values, the values
for plasma ketone bodies were shown to be the
highest in the low-to-medium group at every
evaluation visit (at weeks 12, 24, 36, and 52) (see
Supplemental Figure 4 in the online version at
http://dx.doi.org/10.1016/j.clinthera.2016.01.017). The
median values of β-hydroxybutyric acid at week 52 were
109.0, 87.5, 75.3, 79.8, and 71.0 μmol/L (ranked in
order from the low-to-medium group to the very-
high group, respectively). The results of other laboratory
parameters are described in Table IV and Supplemental
Table III (as shown in the online version at http://dx.doi.
org/10.1016/j.clinthera.2016.01.017).DISCUSSION
This pooled analysis showed that luseogliﬂozin pro-
duced signiﬁcant or clinically relevant reductions in
glycemic parameters and body weight in patients with
T2DM at varying levels of BMI, suggesting the
usefulness of luseogliﬂozin in these patients, regardless
of their BMI or obesity status. At the same time,
luseogliﬂozin was shown to produce greater reduc-
tions in these parameters as well as favorable effects
for some metabolic parameters, including blood pres-
sure, triglyceride levels, hepatic parameters, and uric
acid, in the groups with higher BMI levels. In addition,
for many of these parameters, the favorable effects
induced by luseogliﬂozin were evident in the very-high
group (BMI Z30 kg/m2). Thus, luseogliﬂozin may be
expected to confer greater beneﬁts in patients who
tend to be obese, especially those with very-high BMI
levels. Given that abnormalities in glucose metabolism
are known to be associated with obesity and that the
increase in the obese population is a global issue,3 the
ﬁndings of this pooled analysis can be of particular
interest to current diabetes management. Furthermore,
some OHAs may not be suitable for obese patients;
insulin and sulfonylureas have a risk of increas-
ing body weight,23–25 and the effects of dipeptidyl
peptidase-4 inhibitors are diminished in patients whoApril 2016are overweight or obese.26,27 Considering the chal-
lenges of these other agents, luseogliﬂozin could be a
promising therapeutic option for diabetes care.
As for glycemic parameters, luseogliﬂozin produced
signiﬁcant decreases in HbA1c and FPG in all groups
regardless of BMI level, although the decrease tended
to be slightly small in patients of the low-to-medium
group (BMI o22.5 kg/m2). However, consistent with
earlier analyses of the efﬁcacy of OHAs, the baseline
HbA1c level also greatly affects the decrease in
HbA1c.28 Luseogliﬂozin produced greater reductions
in HbA1c in patients with high baseline HbA1c
values, regardless of their BMI levels (range, –0.91%
to –1.18% in patients with baseline HbA1c levels
Z8%). This ﬁnding suggests that luseogliﬂozin may
offer glucose-lowering beneﬁts for patients at any BMI
level.
It remains unclear why the glucose-lowering efﬁ-
cacy of luseogliﬂozin was greater in patients with
higher BMI levels. There are 2 possible reasons for
this outcome. First, the distribution of baseline HbA1c
levels was slightly different between groups, which
may have affected the results. Because the proportion
of patients with higher baseline HbA1c levels seemed
to be lower in the low-to-medium group (Table I), the
mean change in HbA1c in this group might tend to be
small in this analysis. From another perspective, this
ﬁnding could be a reﬂection of a clinical setting
wherein the groups have not been divided on the
basis of HbA1c and thus could be a true reﬂection of
the correlation between BMI and HbA1c. Second,
factors other than urinary glucose excretion, which is
the direct effect of SGLT2 inhibitors, may have
exerted an additional glucose-lowering effect; the
improvement in insulin resistance and/or sensitivity
could have contributed to the effect, especially in
patients with higher BMI levels. Indeed, these im-
provements were partly indicated by the present data
analysis. The higher the baseline BMI level, the higher
the levels of baseline fasting insulin and C-peptide
immunoreactivity were observed. These parameters
were signiﬁcantly decreased by luseogliﬂozin in all
groups, and the decrease tended to be greater in the
higher BMI groups. In other words, high insulin
resistance in patients with higher BMI was reduced
by treatment of luseogliﬂozin, which in turn might
contribute to the decrease in insulin requirement.
Thus, an additional glucose-lowering effect due to
the improvement in insulin resistance or sensitivity is857
Clinical Therapeuticsexpected to be larger when SGLT2 inhibitors are
administered in patients with higher BMI.
The improvement in insulin resistance induced by
luseogliﬂozin might be partly due to weight loss.
Some studies showed that weight loss could be
beneﬁcial in normalizing hyperglycemia and improv-
ing insulin resistance.29–31 Furthermore, the decrease
in intra-abdominal fat accumulation might have con-
tributed to the decrease of insulin resistance.32
Indeed, previous studies had reported that two
thirds of the weight loss due to SGLT2 inhibitors is
fat mass, and one half of this fat mass is visceral
fat.33,34 The results from this pooled analysis also
might suggest a loss of body fat mass; the initial
weight loss might be due to loss of body ﬂuid (volume
depletion) followed by a loss of fat thereafter.
We observed that an initial decrease in body weight
was rapid up to approximately week 8 in all groups,
and that this decrease then slowed in the lower BMI
groups but continued in the higher BMI groups.
Hemoglobin and hematocrit levels increased up to
week 12 and plateaued thereafter. Taken together,
body fat mass could be decreased in the later phase
after initiation of luseogliﬂozin, especially in patients
with higher BMI levels. In addition, the diminishing
glucotoxicity as a result of rapid normalization of
hyperglycemia might contribute to the improvement
in insulin resistance. A previous pharmacodynamics
study of luseogliﬂozin in patients with T2DM showed
that luseogliﬂozin signiﬁcantly and rapidly decreased
blood glucose levels within 1 day.35 Thus, there is a
possibility that luseogliﬂozin efﬁciently improved
hyperglycemia via a decrease of insulin resistance.
However, the improvement of insulin resistance/
sensitivity cannot be directly evaluated in current
studies, and further studies are needed to clarify
these ﬁndings.
Blood pressure, triglyceride levels, hepatic param-
eters (ALT and AST), and uric acid levels tended to
decrease with luseogliﬂozin in all groups regardless
of BMI level (except for AST in the low-to-medium
group), but the decreases were shown to be greater
in patients with higher BMI. Given that all of these
parameters are likely to be elevated in obese indi-
viduals,36,37 it was suggested that treatment with
luseogliﬂozin provides additional favorable effects
in such patients. With the ﬁnal goal of diabetes
treatment being preventing the development and
progression of complications, total health care858management is essential, including controlling the
risk factors of macrovascular and microvascular
complications. Therefore, patients require better
treatment options, such as luseogliﬂozin, which can
correct a wide variety of metabolic abnormalities in
addition to hyperglycemia.
A notable improvement in metabolic parameters
was observed in the present study, and not only in
patients with very-high BMI levels; a clear improve-
ment was also observed in patients with BMI Z22.5
kg/m2. Although the improvement was small in
patients with BMI o22.5 kg/m2, this outcome might
be due to the proximity of the baseline to the normal
range for these parameters (Table I). The risk of
chronic disease such as diabetes mellitus and
coronary heart disease is generally ‘increased’ in
the population categorized as pre-obese (BMI Z25 to
o30 kg/m2) based on the classiﬁcation of obesity by the
World Health Organization; in the Asian population,
however, individuals with BMI Z23 to o25 kg/m2 are
classiﬁed as ‘increased’ for comorbidity risks.38
Luseogliﬂozin can provide better control of glycemic
parameters and body weight, as well as metabolic pa-
rameters, and would be favorable for a wide range of
patients, including those not classiﬁed as obese (o25 kg/m2
in Japan). In other words, luseogliﬂozin could
improve their general health status in the early
stages, thus allowing the prevention of comorbidities.
Luseogliﬂozin was conﬁrmed as well tolerated in all
groups in this pooled analysis, with no apparent
between-group differences with regard to the inci-
dence of AEs, including AEs of special interest.
Although there were no apparent differences in
changes in hematocrit, hemoglobin, and blood urea
nitrogen between BMI groups, they all signiﬁcantly
increased from baseline for all groups, most likely due
to volume depletion. The change in these parameters
was considered to be increasing from baseline until
about week 12 and plateauing thereafter, suggesting
the need to monitor patients for volume depletion or
dehydration, particularly in the initial phase of treat-
ment with luseogliﬂozin.
Increases in plasma ketone body levels after treat-
ment with SGLT2 inhibitors have been frequently
reported in the Japanese population, and the US Food
and Drug Administration also made a safety an-
nouncement about ketoacidosis and SGLT2 inhibitors
in May 2015.39 In this pooled analysis, the median
values for the increase in plasma ketone bodies tendedVolume 38 Number 4
S. Sakai et al.to be higher in the groups with lower BMI levels,
although a signiﬁcant increase was observed in all
groups. It was also shown that the lower the BMI level,
the lower the baseline C-peptide immunoreactivity and
C-peptide immunoreactivity index values and the
longer the duration of diabetes (Table I), indicating
lower insulin-secretory capacity. In this regard, the
Asian population including the Japanese and partic-
ularly non-obese individuals, have a lower insulin-
secretory capacity than the Western population.40 This
factor could account for the relatively large number
of reports about increases in plasma ketone bodies,
especially in Japan. For the consideration of safety,
SGLT2 inhibitors should not be administered to
the following patients: patients with impaired
insulin secretion or a deﬁciency in insulin effect,
patients unable to consume enough food due to
illness, and patients under a strict low-carbohydrate
diet or at risk of developing an increase in ketone
bodies.
Although the changes in body weight were smaller in
patients with lower BMI levels, excessive weight loss
could be a concern in these patients. Previous studies
conducted outside Japan have examined the cause of
weight loss by other SGLT2 inhibitors.33,34 Because
those investigations were based on the Western popula-
tion with mean BMI levels Z30 kg/m2, further studies
that elucidate the cause of weight loss in the Asian
population including the Japanese, as well as those that
investigate the risk of skeletal muscle mass loss or
sarcopenia, and not only body fat mass, in patients of
a thin body type, are warranted.
The present pooled analysis has several limita-
tions. The sample size was small, and the treatment
period was limited to 52 weeks. In addition, this
analysis included open-label studies, although they
were conducted in accordance with the Japanese
guidelines for clinical trials and new drug applica-
tions.19,20 Moreover, the combination therapies are a
confounding factor in this simple pooled analysis
that did not assign weight to each data point but
treated data as if derived from a single sample.
Hence, the positive efﬁcacy results may not be due
to luseogliﬂozin alone. Luseogliﬂozin should be
investigated in a variety of patient populations to
establish its long-term safety and efﬁcacy proﬁle, as
well as to elucidate prognostic factors for its efﬁcacy
and safety and to enhance the efﬁcient use of SGLT2
inhibitors in clinical practice.April 2016CONCLUSIONS
Luseogliﬂozin was shown to provide signiﬁcant improve-
ments in glycemic parameters and body weight regardless
of BMI level. The decrease in glycemic parameters tended
to be slightly smaller in patients with BMIo22.5 kg/m2,
and greater reductions were observed in patients with
BMI Z22.5 kg/m2. Moreover, decreases in body weight
and fasting insulin levels and improvements in metabolic
abnormalities, including hypertension and triglyceridemia,
were observed, especially in those with higher BMI levels.
The 52-week administration of luseogliﬂozin showed a
favorable and similar safety proﬁle across all groups of
varying BMI levels, with no safety issues identiﬁed. The
efﬁcacy and safety data from the present analysis suggest
that luseogliﬂozin can be an effective and well-tolerated
therapeutic option in T2DM patients with a wide range
of BMI levels, and it may be more beneﬁcial in patients
with a higher BMI.ACKNOWLEDGMENTS
The authors express their gratitude to the patients, in
addition to the investigators and staff at the study sites, for
their contributions to the study. The authors acknowledge
the medical writing assistance provided by Mr. Hiroaki
Itoh and editorial assistance provided by Dr. Shama Buch
of Cactus Communications, which was funded by Taisho
Toyama Pharmaceuticals Co., Ltd. The authors retained
full control of the manuscript content.
AUTHOR CONTRIBUTIONS
Soichi Sakai contributed to the planning and design of
the studies, collection and interpretation of data, and
writing and revision of the manuscript. Drs. Kaku,
Seino, Inagaki, Haneda, Sasaki, and Fukatsu provided
counseling on proceeding with the studies, interpreta-
tion of data, and review and revision of the manu-
script. Haruka Kakiuchi and Yoshishige Samukawa
contributed to the planning and design of the studies,
collection and interpretation of data, and review and
revision of the manuscript. All authors were involved
in the decision to submit the manuscript for publica-
tion and approved the ﬁnal submitted version.CONFLICTS OF INTEREST
S. Sakai, H. Kakiuchi, and Y. Samukawa are full-
time employees of Taisho Pharmaceutical Co., Ltd.
K. Kaku report advisory board consulting fees,859
Clinical Therapeuticsconsulting fees, lecture fees, guidance fees, supervising
fees, payment for manuscript writing, research sup-
port, or grants from AstraZeneca, Boehringer Ingel-
heim, Daiichi Sankyo, Sumitomo Dainippon, Kowa,
MSD, Novartis, Novo Nordisk, Takeda, Sanoﬁ,
Sanwa Kagaku Kenkyusho, Tanabe Mitsubishi,
Taisho Toyama, and Taisho. Y. Seino reports con-
sulting fees or lecture fees, advisor fees, moderator
fees, payment for manuscript writing, or research
support from Sanoﬁ, Novo Nordisk, Eli Lilly, Glaxo
SmithKline, Astellas, Takeda, Boehringer Ingelheim,
Johnson & Johnson, Becton Dickinson, AstraZeneca,
MSD, Ono, Kyowa Hakko Kirin, Kao, Daiichi
Sankyo, Tanabe Mitsubishi, Sumitomo Dainippon,
Novartis, Bristol-Myers Squibb, Kissei, Terumo,
Kowa, Taisho Toyama, and Taisho. N. Inagaki
reports advisory board consulting fees, consulting
fees, lecture fees, moderator fees, grants or research
support from Takeda, GlaxoSmithKline, Tanabe Mit-
subishi, MSD, Sanoﬁ, Novartis, Sumitomo Dainip-
pon, Kyowa Hakko Kirin, Eli Lily, Shiratori, Roche
Diagnostics, Japan Diabetes Foundation, JT, Boeh-
ringer Ingelheim, Astellas, Daiichi Sankyo, Ono,
AstraZeneca, Kowa, Taisho Toyama, and Taisho.
M. Haneda reports consulting fees, lecture fees, mod-
erator fees, supervising fees, payment for manuscript
writing, research support, or grants from Sanoﬁ,
Tanabe Mitsubishi, Takeda, Eli Lilly, Boehringer
Ingelheim, Novo Nordisk, Novartis, MSD, Kyowa
Hakko Kirin, Daiichi Sankyo, Astellas, Kowa, Asahi
Kasei Pharma, Ajinomoto Pharma, Otsuka, Ono,
Kaken, Kissei, GlaxoSmithKline, Sanwa Kagaku
Kenkyusho, Shionogi, Johnson & Johnson, Sumitomo
Dainippon, Chugai, Teijin Pharma, Terumo, Torii,
Bayer Yakuhin, Pﬁzer, Bristol-Myers Squibb, Mochida,
Roche Diagnostics, AstraZeneca, Taisho Toyama, and
Taisho. T. Sasaki reports consulting fees, lecture fees,
payment for manuscript writing, research support, or
grants from Canon Inc., Sanoﬁ, Kowa, Tanabe Mitsu-
bishi, Novo Nordisk, MSD, LIGHT Study Group
(LIGHT Study; UMIN ID 000015112), Taisho
Toyama, and Taisho. A. Fukatsu reports consulting
fees or lecture fees from Taisho Toyama and Taisho.
The authors have indicated that they have no other
conﬂicts of interest related to these studies.
The design and implementation of the present study
were overseen by the advisory board together with
representatives of the sponsor. The sponsor collected
the study data and monitored the study sites.860SUPPLEMENTARY MATERIALS
Supplementary data associated with this article can be
found in the online version at http://dx.doi.org/
10.1016/j.clinthera.2016.01.017.REFERENCES
1. International Diabetes Federation. IDF Diabetes Atlas,
Sixth edition. http://www.idf.org/sites/default/ﬁles/EN_
6E_Atlas_Full_0.pdf. Accessed February 13, 2015.
2. World Health Organization. BMI Classiﬁcations http://
www.who.int/mediacentre/factsheets/fs311/en/. Accessed
July 1, 2015.
3. Ng M, Fleming T, Robinson M, et al. Global, regional,
and national prevalence of overweight and obesity in
children and adults during 1980-2013: a systematic
analysis for the Global Burden of Disease Study 2013.
Lancet. 2014;384:766–781.
4. Japan Diabetes Clinical Data Management Study Group.
Basic study. http://jddm.jp/data/index.html. Accessed
February 13, 2015.
5. Japan Society for the Study of Obesity. Diagnostic
criterion of obesity 2011. J Japan SocStud Obes. 2011;17
(extra edition):1–78.
6. Center for Disease Control and Prevention. Age-adjusted
percentage of adults aged 18 years or older with diag-
nosed diabetes who were obese, United States, 1994–
2010. http://www.cdc.gov/diabetes/statistics/comp/ﬁg7_
obesity.htm. Accessed February 13, 2015.
7. Centers for Disease Control and Prevention. Age-adjusted
percentage of adults aged 18 years or older with
diagnosed diabetes who were overweight, United
States, 1994–2010. http://www.cdc.gov/diabetes/statistics/
comp/ﬁg7_overweight.htm. Accessed February 13, 2015.
8. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deﬁcit
and increased beta-cell apoptosis in humans with type 2
diabetes. Diabetes. 2003;52:102–110.
9. Peene B, Benhalima K. Sodium glucose transporter
protein 2 inhibitors: focusing on the kidney to treat type
2 diabetes. Ther Adv Endocrinol Metab. 2014;5:124–136.
10. Riser Taylor S, Harris KB. The clinical efﬁcacy and safety
of sodium glucose cotransporter-2 inhibitors in adults
with type 2 diabetes mellitus. Pharmacotherapy. 2013;33:
984–999.
11. Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel,
potent and selective renal sodium-glucose cotransporter
2 (SGLT2) inhibitor with antihyperglycaemic activity. Br J
Pharmacol. 2011;164:181–191.
12. Uchida S, Mitani A, Gunji E, et al. In vitro characterization
of luseogliﬂozin, a potent and competitive sodium glu-
cose co-transporter 2 inhibitor: inhibition kinetics and
binding studies. J Pharmacol Sci. 2015;128:54–57.Volume 38 Number 4
S. Sakai et al.13. Hasegawa M, Chino Y, Horiuchi N,
et al. Preclinical metabolism and
disposition of luseogliﬂozin, a novel
antihyperglycemic agent. Xenobiotica.
2015;45:1105–1115.
14. Seino Y, Sasaki T, Fukatsu A, et al.
Efﬁcacy and safety of luseogliﬂozin
as monotherapy in Japanese patients
with type 2 diabetes mellitus: a
randomized, double-blind, placebo-
controlled, phase 3 study. Curr Med
Res Opin. 2014;30:1245–1255.
15. Seino Y, Inagaki N, Haneda M, et al.
Efﬁcacy and safety of luseogliﬂozin
added to various oral antidiabetic
drugs in Japanese patients with type
2 diabetes mellitus. J Diabetes Invest.
2015;6:443–453.
16. Seino Y, Kaku K, Inagaki N, et al.
Fifty-two-week long-term clinical
study of luseogliﬂozin as monother-
apy in Japanese patients with type 2
diabetes mellitus inadequately con-
trolled with diet and exercise. Endocr J.
2015;62:593–603.
17. Haneda M, Seino Y, Inagaki N, et al.
Inﬂuence of renal function on the
52-week efﬁcacy and safety of
SGLT2 inhibitor luseogliﬂozin in Jap-
anese patients with type 2 diabetes
mellitus. Clin Ther. 2016;38:66–88.
e20.
18. Guideline for Clinical Evaluation of
Oral Hypoglycemic Agents. Director,
Evaluation and Licensing Division,
Pharmaceutical and Food Safety Bu-
reau, Ministry of Health, Labour
and Welfare. PFSB/ELD Notiﬁcation
No. 0709-1, July 9, 2010. http://
www.pmda.go.jp/ﬁles/000208194.
pdf. Accessed February 19, 2016.
19. ICH harmonised tripartite guideline.
The extent of population exposure
to assess clinical safety for drugs
intended for long-term treatment of
non-life-threatening conditions.
http://www.pmda.go.jp/ﬁles/
000156791.pdf.
20. Harmonisation for better health. Efﬁ-
cacy guidelines. http://www.ich.org/
products/guidelines/efﬁcacy/article/ef
ﬁcacy-guidelines.html. Accessed Feb-
ruary 13, 2015.April 201621. Committee of the Japan Diabetes
Society on the Diagnostic Criteria
of Diabetes Mellitus. Seino Y,
Nanjo K, Tajima N, et al, Report of
the committee on the classiﬁcation
and diagnostic criteria of diabetes
mellitus. J Diabetes Invest. 2010;1:
212–228.
22. Kashiwagi A, Kasuga M, Araki E,
et al. Committee on the Standard-
ization of Diabetes Mellitus‐Related
Laboratory Testing of Japan Diabe-
tes Society. International clinical
harmonization of glycated hemoglo-
bin in Japan: from Japan Diabetes
Society to National Glycohemoglo-
bin Standardization Program values.
J Diabetes Investig. 2012;3:39–40.
23. UK Prospective Diabetes Study
(UKPDS) Group. Intensive blood-
glucose control with sulphonylureas
or insulin compared with conven-
tional treatment and risk of compli-
cations in patients with type 2
diabetes (UKPDS 33). Lancet. 1998;
352:837–853.
24. Yki-Järvinen H, Ryysy L, Kauppila M,
et al. Effect of obesity on the re-
sponse to insulin therapy in
noninsulin-dependent diabetes mel-
litus. J Clin Endocrinol Metab. 1997;
82:4037–4043.
25. United Kingdom Prospective Diabe-
tes Study Group. United Kingdom
Prospective Diabetes Study 24: a 6-
year, randomized, controlled trial
comparing sulfonylurea, insulin,
and metformin therapy in patients
with newly diagnosed type 2 diabe-
tes that could not be controlled with
diet therapy. Ann Intern Med. 1998;
128:165–175.
26. Kim YG, Hahn S, Oh TJ, et al.
Differences in the glucose-lowering
efﬁcacy of dipeptidyl peptidase-4
inhibitors between Asians and non-
Asians: a systematic review and
meta-analysis. Diabetologia. 2013;56:
696–708.
27. Nomiyama T, Akehi Y, Takenoshita H,
et al. CHAT. Contributing factors
related to efﬁcacy of the dipeptidyl
peptidase-4 inhibitor sitagliptin inJapanese patients with type 2 diabe-
tes. Diabetes Res Clin Pract. 2012;95:
e27–e28.
28. Bloomgarden ZT, Dodis R, Viscoli
CM, et al. Lower baseline glycemia
reduces apparent oral agent
glucose-lowering efﬁcacy: a meta-
regression analysis. Diabetes Care.
2006;29:2137–2139.
29. CADTH Rapid Response Reports.
Obesity interventions delivered in
primary care for patients with dia-
betes: a review of clinical effective-
ness [Internet]. Ottawa (ON):
Canadian Agency for Drugs and
Technologies in Health; 2014 Jun.
30. Colberg SR, Albright AL, Blissmer BJ,
et al. American College of Sports
Medicine; American Diabetes Asso-
ciation. Exercise and type 2 diabetes:
American College of Sports Medi-
cine and the American Diabetes
Association: joint position state-
ment. Exercise and type 2 diabetes.
Med Sci Sports Exerc. 2010;42:2282–
2303.
31. Pi-Sunyer FX. A review of long-term
studies evaluating the efﬁcacy of
weight loss in ameliorating disorders
associated with obesity. Clin Ther.
1996;18:1006–1035.
32. Frayn KN. Visceral fat and insulin
resistance-causative or correlative?
Br J Nutr. 2000;83(Suppl 1):S71–S77.
33. Bolinder J, Ljunggren Ö, Kullberg J,
et al. Effects of dapagliﬂozin on
body weight, total fat mass, and
regional adipose tissue distribution
in patients with type 2 diabetes
mellitus with inadequate glycemic
control on metformin. J Clin Endocrinol
Metab. 2012;97:1020–1031.
34. Cefalu WT, Leiter LA, Yoon KH,
et al. Efﬁcacy and safety of canagli-
ﬂozin versus glimepride in patients
with type 2 diabetes inadequately
controlled with metformin (CAN-
TATA-SU): 52 week results from a
randomized, double-blind, phase 3
non-inferiority trial. Lancet. 2013;
382:941–950.
35. Sasaki T, Seino Y, Fukatsu A, et al.
Pharmacokinetics,861
Clinical Therapeuticspharmacodynamics, and safety of
luseogliﬂozin in Japanese patients
with type 2 diabetes mellitus: a
randomized, single-blind, placebo-
controlled trial. Adv Ther. 2015;32:
319–340.
36. Mathieu P, Poirier P, Pibarot P, et al.
Visceral obesity. The link among
inﬂammation, hypertension, and
cardiovascular disease. Hypertension.
2009;53:577–584.
37. Kamada Y, Nakamura T, Funahashi T,
et al. Visceral obesity and hypoadipo-
nectinemia are signiﬁcant determi-
nants of hepatic dysfunction: an
epidemiological study of 3827 Japa-
nese subjects. J Clin Gastroenterol. 2009;
43:995–1000.
38. World Health Organization. The
Asian Paciﬁc Perspective: Redeﬁning
Obesity and its Treatment. Health
Communications Australia Pty Ltd.;
February 2000. Section 2, p 17-20.
39. FDA Drug Safety Communication:
FDA warns that SGLT2 inhibitors
for diabetes may result in a serious
condition of too much acid in the
blood [05-15-2015]. http://www.fda.
gov/drugs/drugsafety/ucm446845.
htm. Accessed July 1, 2015.
40. Iwahashi H, Okauchi Y, Ryo M,
et al. Insulin-secretion capacity in
normal glucose tolerance, impaired
glucose tolerance, and diabetes in
obese and non-obese Japanese
patients. J Diabetes Invest. 2012;3:
271–275.862Address correspondence to: Soichi Sakai, Bachelor of Pharmacy, Taisho
Pharmaceutical Co., Ltd., 3-24-1, Takada, Toshima-ku, Tokyo 170-8633,
Japan. E-mail: so-sakai@so.taisho.co.jpVolume 38 Number 4
S
U
P
T
abAp
ril
2
0
1
6
8
6
2
.e1P
LE
M
les
SI,
e pooled analysis.
Renal impairmentSupplemental Table I. Studies included in th
Add-onE
N
SII
Add-on MonotherapyT
A
an(TS071-03-4)Study (TS071-03-1)RdS
Study registry number JapicCTI-111507
Study design 24-week placebo-controlled
RCT followed by a
28-week open-label study
Concomitant
pharmacological
treatment
SU
Exposure duration
Dose of luseogliﬂozin
Major criteria
Criteria for eGFR,
(mL/min/1.73m2)
No. of patients
included in the
pooled analysis, n
150
Low-to-medium
(BMI o 22.5 kg/m2),
n
39
Medium (BMI Z 22.5
to o 25 kg/m2), n
50
High-level 1 (BMIZ 25
to o 27.5 kg/m2), n
30
16(TS071-03-2) (TS071-03-3)Y
M
A
T
E
R
IA
LS
III.
JapicCTI-111508 JapicCTI-111509 JapicCTI-111543
Open-label study Open-label
study
24-week placebo-controlled
RCT followed by a
28-week open-
label study
BG, DPP4i, TZD,
glinides, or
α-GI
None (diet/exercise
therapy alone)
Enable to use up to 2 oral
hypoglycemic agents
52 weeks
2.5 mg/day (allowed to increase up to 5 mg/day after week 24)
HbA1c Z 6.9% to r 10.5%, Age Z 20 years
Z 45 Z 30 to o 60
487 299 95
99 60 24
121 72 27
122 90 20
77 37 12
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Study
Add-on Add-on Monotherapy Renal impairment
(TS071-03-1) (TS071-03-2) (TS071-03-3) (TS071-03-4)
High-level 2 (BMI Z
27.5 to o 30 kg/m2),
n
Very-high (BMI Z
30 kg/m2), n
15 68 40 12
α-GI ¼ α-glucosidase inhibitor; BG ¼ biguanide; BMI ¼ body mass index; DPP4i ¼ dipeptidyl peptidase-4 inhibitor; eGFR ¼ estimated glomerular
ﬁltration rate; HbA1c ¼ glycosylated hemoglobin; RCT ¼ randomized controlled trial; SU ¼ sulfonylurea; TZD ¼ thiazolidinedione.
Supplemental Table II. Subgroup analysis based on the baseline SBP.
Low-to-medium Medium High-level 1 High-level 2 Very-high
BMI levels
(kg/m2) o22.5 Z22.5 to o25 Z25 to o27.5 Z27.5 to o30 Z30
Baseline SBP category (mm Hg) o130 Z130 o130 Z130 o130 Z130 o130 Z130 o130 Z130
No. (%) of patients at
baseline
151
(68.0)
71
(32.0)
151
(55.9)
119
(44.1)
136
(51.9)
126
(48.1)
58
(40.8)
84
(59.2)
55
(40.7)
80
(59.3)
No. of patients at week 52 127 60 139 109 132 117 53 78 50 76
SBP (mm Hg)
Baseline, mean  SD 114.2
 9.4
140.5
 9.3
117.5
 7.9
141.8
 9.0
118.2
 9.1
140.0
 9.1
121.2
 6.0
142.0
 9.4
119.6
 7.2
140.8
 8.9
Change at 52 week,
mean (95% CI)
1.2
(0.9, 3.3)
10.3
(13.0, 7.5)**
0.3
(1.7, 2.3)
9.9
(12.2, 7.6)**
0.5
(2.6, 1.6)
10.7
(13.0, 8.3)**
1.9
(5.1, 1.3)
9.7
(12.2, 7.2)**
0.1
(3.6, 3.4)
9.3
(12.0, 6.7)**
BMI ¼ body mass index; CI ¼ conﬁdence interval; SBP ¼ systolic blood pressure; SD ¼ standard deviation.
**P o 0.001 vs baseline, 1 sample t-test.
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Supplemental Table III. Changes in laboratory parameters from baseline to week 52 for all BMI groups who received luseogliflozin.
Low-to-Medium Medium High-level 1 High-level 2 Very-high
BMI levels (kg/m2) o 22.5 Z 22.5 to o 25 Z 25 to o 27.5 Z 27.5 to o 30 Z 30
No. of patients at baseline 222 270 262 142 135
No. of patients at week 52 187 248 249 131 126
BUN (Cr-corrected) At baseline 21.87  6.30 19.85  5.68 20.55  6.15 20.79  6.17 19.92  5.71
(g/g Cr) Changes at week 52 2.75 (1.97, 3.53)** 3.55 (2.93, 4.16)** 2.74 (2.05, 3.44)** 2.05 (1.18, 2.92)** 1.25 (0.37, 2.14)*
Cystatin C (mg/L) At baseline 0.78  0.22 0.77  0.17 0.78  0.17 0.78  0.15 0.79  0.18
Changes at week 52 0.05 (0.04, 0.06)** 0.05 (0.04, 0.06)** 0.04 (0.03, 0.05)** 0.05 (0.04, 0.06)** 0.04 (0.03, 0.05)**
Urinary NAG (Cr-corrected) At baseline 9.50  5.34 8.97  5.98 8.86  6.83 7.80  4.47 9.17  5.92
(U/g Cr) Changes at week 52 1.51 (0.89, 2.14)** 0.98 (0.32, 1.63)* 1.20 (0.53, 1.86)** 1.45 (0.64, 2.26)** 0.71 (0.10, 1.53)
Urinary β2 microglobulin At baseline 293.5  548.6 349.9  1192.5 265.4  670.3 163.3  227.6 204.6  517.7
(Cr-corrected) (μg/g Cr) Changes at week 52 111.8 (12.1, 211.6)* 225.9 (75.9, 375.8)* 98.0 (43.8, 152.1)** 118.5 (32.5, 204.5)* 34.3 (0.9, 69.4)
Na (mEq/L) At baseline 139.50  1.90 139.63  2.02 139.50  1.92 139.68  1.96 139.37  1.65
Changes at week 52 0.41 (0.15, 0.68)* 0.50 (0.26, 0.75)** 0.51 (0.26, 0.75)** 0.61 (0.27, 0.95)** 0.65 (0.33, 0.97)**
Cl (mEq/L) At baseline 102.22  2.32 102.26  2.28 102.15  2.19 102.38  2.24 101.81  1.94
Changes at week 52 0.02 (-0.29, 0.32) 0.24 (0.04, 0.52) 0.34 (0.09, 0.60)* 0.32 (0.03, 0.67) 0.29 (0.04, 0.62)
Ca (mg/dL) At baseline 9.15  0.33 9.18  0.33 9.19  0.32 9.20  0.29 9.14  0.31
Changes at week 52 0.04 (0.00, 0.08) 0.04 (0.00, 0.08)* 0.03 (0.01, 0.06) 0.03 (0.02, 0.08) 0.04 (0.00, 0.09)
K (mEq/L) At baseline 4.25  0.33 4.18  0.30 4.15  0.31 4.19  0.31 4.07  0.30
Changes at week 52 0.04 (0.08, 0.01) 0.03 (0.07, 0.00) 0.02 (0.06, 0.01) 0.08 (0.13, 0.03)* 0.03 (0.08, 0.02)
Mg (mg/dL) At baseline 2.15  0.16 2.13  0.17 2.14  0.16 2.12  0.16 2.09  0.17
Changes at week 52 0.10 (0.08, 0.11)** 0.11 (0.09, 0.12)** 0.09 (0.08, 0.11)** 0.12 (0.10, 0.14)** 0.12 (0.09, 0.14)**
P (mg/dL) At baseline 3.29  0.45 3.22  0.44 3.26  0.45 3.32  0.45 3.28  0.40
Changes at week 52 0.07 (0.02, 0.12)* 0.14 (0.10, 0.19)** 0.09 (0.04, 0.13)** 0.08 (0.02, 0.14)* 0.08 (0.01, 0.15)*
BAP (μg/L) At baseline 14.25  5.29 15.00  6.11 14.84  5.54 14.63  6.13 15.41  7.24
Changes at week 52 0.52 (1.15, 0.11) 0.76 (1.14, -0.38)** 1.13 (1.61, 0.66)** 0.53 (1.03, 0.02)* 0.84 (1.49, 0.18)*
NTx (nM BCE/L) At baseline 15.94  4.93 16.00  5.29 15.66  6.18 15.61  4.25 15.62  5.19
Changes at week 52 2.29 (1.59, 3.00)** 2.07 (1.55, 2.58)** 2.27 (1.70, 2.83)** 2.34 (1.64, 3.03)** 1.47 (0.74, 2.20)**
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Supplemental Table III. (continued).
Low-to-Medium Medium High-level 1 High-level 2 Very-high
BMI levels (kg/m2) o 22.5 Z 22.5 to o 25 Z 25 to o 27.5 Z 27.5 to o 30 Z 30
1α, 25-(OH)2 vitamin D At baseline 62.99  27.35 62.94  28.90 62.96  26.38 57.04  24.49 60.01  27.68
(pg/mL) Changes at week 52 4.75 (9.14, 0.36)* 4.10 (8.10, 0.10)* 7.23 (10.70, 3.76)** 1.49 (6.04, 3.06) 7.52 (12.40, 2.65)*
Intact PTH (pg/mL) At baseline 45.29  15.37 46.89  15.72 45.69  16.61 48.55  17.17 51.79  18.76
Changes at week 52 2.61 (1.11, 4.12)** 3.09 (1.79, 4.40)** 2.99 (1.53, 4.45)** 4.63 (2.58, 6.68)** 3.78 (1.51, 6.05)*
BAP ¼ bone-speciﬁc alkaline phosphatase; BCE ¼ bone collagen equivalents; BMI ¼ body mass index; BUN ¼ blood urea nitrogen; Ca ¼ calcium; CI ¼ conﬁdence
interval; Cl ¼ chloride; Cr ¼ creatinine; K ¼ potassium; Mg ¼ magnesium; NAG ¼ N-acetyl-β-D-glucosaminidase; Na ¼ sodium; NTx ¼ N-terminal crosslinking
telopeptide of type I collagen; P ¼ phosphorus; PTH ¼ parathyroid hormone; SD ¼ standard deviation.
Data are presented as mean  SD for baseline values and mean (95% CI) for changes at week 52.
*P o 0.05, vs. baseline, one sample t-test.
**P o 0.001 vs. baseline, one sample t-test.
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Pooled population
A
n=1152
n=121
n=121
Excluded
Patients who received placebo in
double-blind period (in TS071-03-1 or 03-4 studies)
Four phase III studies (TS071-03-1, 03-2, 03-3, 03-4)
Pooled analysis set
n=1031
Week 0
Treatment
period for
52 weeks
 complete
Low-to-medium
(baseline BMI
< 22.5 kg/m2)
n=222
Low-to-medium
(baseline BMI
< 22.5 kg/m2)
n=187
Medium High-level 1
(baseline BMI
≥ 22.5 to < 25 kg/m2)
n=270
Medium
(baseline BMI
≥ 22.5 to < 25 kg/m2)
n=248
(baseline BMI
≥ 25 to < 27.5 kg/m2)
n=262
High-level 1
(baseline BMI
≥ 25 to < 27.5 kg/m2)
n=249
High-level 2
(baseline BMI
≥ 27.5 to < 30 kg/m2)
n=142
High-level 2
(baseline BMI
≥ 27.5 to < 30 kg/m2)
n=131
Very-high
(baseline BMI
≥  30 kg/m2)
n=135
Very-high
(baseline BMI
≥  30 kg/m2)
n=126
Patients who received luseogliflozin at least once
Supplemental Figure 1A. Patient disposition and luseogliflozin treatment arms included in the pooled
analysis. (A) Patient disposition in the pooled analysis. BMI = body mass index.
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Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Increased to Luseogliflozin 5 mg/day
Open-label study
Open-label study
week 0B week 24 week 52
TS071-03-3 study
Luseogliflozin
Luseogliflozin on
in Monotherapy
TS071-03-2 study
TS071-03-4 study
TS071-03-1 study
Add-on therapy
Add-on therapy
to other oral
hypoglycemic agents
to sulfonylurea
Double-blind phase
Double-blind phase
Open-label phase
Open-label phase
Rando-
mization
Rando-
mization
patients with
renal impairment
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Luseogliflozin 2.5 mg/day
Placebo
Placebo
BG, DPP4 inhibitor, TZD, Glinide, or α-GI
SU
SU
Up to two oral hypoglycemic agents
Up to two oral hypoglycemic agents
Increased to Luseogliflozin 5 mg/day
Supplemental Figure 1B. Patient disposition and luseogliflozin treatment arms included in the pooled
analysis. (B) Four luseogliflozin arms of the two open-label studies and two RCTs
included in the pooled analysis. Boxed arms were included in the pooled analysis.
α-GI = α-glucosidase inhibitor; BG = biguanide; BMI = body mass index; DPP4i =
dipeptidyl peptidase-4 inhibitor; OHAs = oral hypoglycemic agents; RCT =
randomized controlled trial; SU = sulfonylurea; TZD = thiazolidinedione.
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Very-high (BMI ≥ 30 kg/m2, n=135)
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Supplemental Figure 2. Changes over 52 weeks in blood pressure and laboratory parameters for all BMI
groups who received luseogliflozin. (A) SBP, (B) DBP, (C) AST, (D) ALT, (E) Hct, (F)
BUN, and (G) eGFR. In Figures (C) and (D), two patients whose ALT and/or AST
showed apparent abnormalities in the low-to-medium group (BMI o 22.5 kg/m2)
were excluded. (E), (F), and (G) are changes from the baseline. Data are presented as
mean ± 95% CI. ALT = alanine aminotransferase; AST = aspartate aminotransferase;
BMI = body mass index; BUN = blood urea nitrogen; CI = confidence interval; DBP
= diastolic blood pressure; eGFR = estimated glomerular filtration rate; Hct =
hematocrit; SBP = systolic blood pressure.
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Supplemental Figure 3. The proportion of patients with high blood pressure and patients with hyperlipidemia
(at weeks 0 and 52). Patients who completed 52 weeks of luseogliflozin therapy were
included. (A) Proportion of patients with SBP ≥130 mm Hg, (B) Proportion of
patients with DBP ≥80 mm Hg, (C) Proportion of patients with triglyceride levels
≥150 mg/dL. 0wk = 0 week; 52wk = 52 week; BMI = body mass index; DBP =
diastolic blood pressure; SBP = systolic blood pressure; TG = triglyceride.
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A
B
Supplemental Figure 4. Changes (median values) over 52 weeks in plasma ketone body levels for all BMI
groups. (A) plasma acetoacetic acid, (B) plasma β-hydroxyacetic acid. Data are
presented as median (25-75 percentile). BMI = body mass index.
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